Considering that cancers are complicated diseases involving multiple pathways and multidrug resistance (MDR) is induced via various and complex mechanisms, several cancers have been treated by combination chemotherapy involving employment of TCH (Taxol, Carboplatin and Herceptin) for HER2/neu-positive tumor and the combination of Platinol (cisplatin) and Navelbine (vinorelbine) for non-small cell lung cancer treatment [45,46]. Here, ERBB2 is linked to non-small cell lung carcinoma.